Phase I study of Tiragolumab in patients with advanced solid tumors
Phase 1
Completed
- Conditions
- Advanced solid tumor
- Registration Number
- JPRN-jRCT2080224926
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
ECOG Performance Status of 0 or 1
- Histologically or cytologically documented solid tumors
- Evaluable lesion by image
Exclusion Criteria
- History of severe adverse reaction by treatment with previous cancer immunotherapy
- History or complication of autoimmune disease
- Meningeal metastasis or metastasis to the central nervous system requiring treatment or accompanied by symptoms
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pharmacokinetics<br>safety<br>Observation/Inspection
- Secondary Outcome Measures
Name Time Method efficacy<br>other<br>Other (Immunogenicity)<br>Observation/Inspection